Abstract：
UNASSIGNED: Disease control is essential to decrease morbidity burden and mortality in acromegaly patients. In the last decades, the availability of new drugs increased the rate of disease control. However, up to 55% of patients remain uncontrolled despite available treatment strategies in real-world data. The reasons for this finding may include poor adherence, inadequate tolerability, therapeutic inertia, and high costs. Since acromegaly is a chronic disease and medical therapy is usually life-long, patient\'s adherence to treatment is fundamental in both achieving and maintaining disease control. Less invasive routes of administration could improve adherence and concur to increase disease control rate.
UNASSIGNED: The aim of current review is to provide a detailed update about investigational drugs for acromegaly treatment currently under investigation as paltusotine, ONO-5788, AP102, GT-02037, ISIS 766720, CAM2024, Lanreotide PRF, DP1038, MTD201, solid dose injection of octreotide.
UNASSIGNED: Medical therapy of acromegaly is an evolving field. Current studies are addressing patient\'s need for both new molecules and less invasive routes of administration for already existing drugs. It cannot be ruled out that drugs currently used for other diseases such as cancer could be considered in the future for the treatment of acromegaly.
UNASSIGNED: The aim of current review is to provide a detailed update about investigational drugs for acromegaly treatment currently under investigation as paltusotine, ONO-5788, AP102, GT-02037, ISIS 766720, CAM2024, Lanreotide PRF, DP1038, MTD201, solid dose injection of octreotide.
UNASSIGNED: Medical therapy of acromegaly is an evolving field. Current studies are addressing patient\'s need for both new molecules and less invasive routes of administration for already existing drugs. It cannot be ruled out that drugs currently used for other diseases such as cancer could be considered in the future for the treatment of acromegaly.
摘要：
疾病控制对于降低肢端肥大症患者的发病负担和死亡率至关重要。在过去的几十年里，新药的出现提高了疾病控制率。然而,尽管在现实世界的数据中可用治疗策略,但高达55%的患者仍然不受控制.这一发现的原因可能包括依从性差，耐受性不足,治疗惯性，和高成本。由于肢端肥大症是一种慢性疾病，药物治疗通常是终身的，患者坚持治疗是实现和维持疾病控制的基础。侵入性较小的给药途径可以提高依从性，并有助于提高疾病控制率。
■当前审查的目的是提供有关目前正在研究的肢端肥大症治疗的研究药物的详细更新，ONO-5788,AP102,GT-02037,ISIS766,720,CAM2024,LanreotidePRF,DP1038，MTD201，固体剂量打针奥曲肽。
■肢端肥大症的药物治疗是一个不断发展的领域。目前的研究正在解决患者对现有药物的新分子和侵入性较小的给药途径的需求。不能排除目前用于其他疾病如癌症的药物将来可以考虑用于治疗肢端肥大症。
■当前审查的目的是提供有关目前正在研究的肢端肥大症治疗的研究药物的详细更新，ONO-5788,AP102,GT-02037,ISIS766,720,CAM2024,LanreotidePRF,DP1038，MTD201，固体剂量打针奥曲肽。
■肢端肥大症的药物治疗是一个不断发展的领域。目前的研究正在解决患者对现有药物的新分子和侵入性较小的给药途径的需求。不能排除目前用于其他疾病如癌症的药物将来可以考虑用于治疗肢端肥大症。
